Solid Biosciences Inc.
SLDBNasdaq
$8.72
↓ -3.6%Jul 17 close · end-of-day
Price
1Y↑ +56.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$957.6M
Enterprise Value
$576.9M
P/E
—
P/S
—
P/B
2.6
EV/EBITDA
—
PEG
—
FCF Yield
-18.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
-$172.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$380.7M
Return 1Y
+50.6%
Company profile
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles.
- CEO
- Ilan Ganot
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- solidbio.com
Earnings
SLDB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.52↓ -11.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $13.6M | $8.1M | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$88.4M | -$72.3M | -$106.5M | -$104.3M | -$129.7M | -$179.2M |
| Net income | — | — | — | — | — | — |
| Diluted EPS | -$25.50 | -$10.14 | -$10.10 | -$4.83 | -$3.06 | -$1.99 |
| Operating cash flow | -$56.6M | -$77.8M | -$98.0M | -$94.2M | -$100.0M | -$156.3M |
| Free cash flow | -$57.5M | -$79.0M | -$101.0M | -$95.7M | -$100.7M | -$157.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -530.5% | -1315.2% | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$27.8M | -$35.2M | -$39.9M | -$40.1M | -$41.7M | -$48.1M | -$49.4M | -$57.3M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$0.61 | -$0.79 | -$1.02 | -$0.59 | -$0.42 | -$0.48 | -$0.50 | -$0.52 |
| Operating cash flow | -$21.5M | -$23.7M | -$29.6M | -$31.9M | -$37.4M | -$33.5M | -$53.6M | -$47.2M |
| Free cash flow | -$21.8M | -$23.7M | -$29.8M | -$32.0M | -$37.8M | -$33.6M | -$54.1M | -$47.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.